The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease
| Autor: | Carl Harries, Michael A. Gatzoulis, Lisa Parfitt, Tamera J. Corte, Athol U. Wells, S. John Wort |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty business.industry medicine.drug_class Sildenafil Interstitial lung disease respiratory system Brain natriuretic peptide medicine.disease Pulmonary hypertension respiratory tract diseases FEV1/FVC ratio chemistry.chemical_compound Endocrinology chemistry Internal medicine cardiovascular system Natriuretic peptide Ventricular pressure Cardiology Medicine business Cohort study |
| Zdroj: | Respirology. 15:1226-1232 |
| ISSN: | 1323-7799 |
| DOI: | 10.1111/j.1440-1843.2010.01860.x |
| Popis: | Background and objective: Limited data suggest a benefit following sildenafil treatment in patients with pulmonary hypertension (PH) and interstitial lung disease (ILD). The role of sildenafil in the management of PH in ILD is not clear. We report our experience of ILD patients with PH after 6-month sildenafil therapy. Methods: We reviewed 15 patients (mean age 55 ± 15 years; 8 men) with ILD (mean FVC 52.6 ± 15.4%) and PH (mean right ventricular systolic pressure 73.8 ± 17.8 mm Hg). Median brain natriuretic peptide: 37 (5–452) pmol/L; mean 6MWD: 156 ± 101 m. Results: Following 6-month treatment with sildenafil, brain natriuretic peptide levels were lower (n = 12, P = 0.03), 6MWD was higher (n = 6, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text